- call +1-201-465-4211
- email sales@mrinsights.biz
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000.
Scope of the Report:
This report focuses on the G-CSF Biosimilars in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for G-CSF Biosimilars in US$ by the following Product Segments: Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor
Company profiles are primarily based on public domain information including company
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Pfizer
Novartis
Roche
The worldwide market for G-CSF Biosimilars is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Pfizer
Novartis
Roche
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Human Growth Hormone
Erythropoietin
Monoclonal Antibodies
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Market Segment by Applications, can be divided into
Blood Disorders
Oncology Diseases
Chronic And Autoimmune Diseases
Growth Hormone Deficiencies
There are 15 Chapters to deeply display the global G-CSF Biosimilars market.
Chapter 1, to describe G-CSF Biosimilars Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of G-CSF Biosimilars, with sales, revenue, and price of G-CSF Biosimilars, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of G-CSF Biosimilars, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, G-CSF Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe G-CSF Biosimilars sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 G-CSF Biosimilars Introduction
1.2 Market Analysis by Type
1.2.1 Human Growth Hormone
1.2.2 Erythropoietin
1.2.3 Monoclonal Antibodies
1.2.4 Insulin
1.2.5 Interferon
1.2.6 Granulocyte-Colony Stimulating Factor
1.3 Market Analysis by Applications
1.3.1 Blood Disorders
1.3.2 Oncology Diseases
1.3.3 Chronic And Autoimmune Diseases
1.3.4 Growth Hormone Deficiencies
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 G-CSF Biosimilars Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 G-CSF Biosimilars Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Roche
2.3.1 Business Overview
2.3.2 G-CSF Biosimilars Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Roche G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck & Co.
2.4.1 Business Overview
2.4.2 G-CSF Biosimilars Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck & Co. G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Sanofi
2.5.1 Business Overview
2.5.2 G-CSF Biosimilars Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Sanofi G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Johnson & Johnson
2.6.1 Business Overview
2.6.2 G-CSF Biosimilars Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Johnson & Johnson G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Gilead Science
2.7.1 Business Overview
2.7.2 G-CSF Biosimilars Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Gilead Science G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 GlaxoSmithKline
2.8.1 Business Overview
2.8.2 G-CSF Biosimilars Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 GlaxoSmithKline G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 AbbVie
2.9.1 Business Overview
2.9.2 G-CSF Biosimilars Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 AbbVie G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Amgen
2.10.1 Business Overview
2.10.2 G-CSF Biosimilars Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Amgen G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 AstraZeneca
2.11.1 Business Overview
2.11.2 G-CSF Biosimilars Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 AstraZeneca G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Bayer
2.12.1 Business Overview
2.12.2 G-CSF Biosimilars Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Bayer G-CSF Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global G-CSF Biosimilars Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global G-CSF Biosimilars Sales and Market Share by Manufacturer (2016-2017)
3.2 Global G-CSF Biosimilars Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 G-CSF Biosimilars Manufacturer Market Share in 2017
3.3.2 Top 6 G-CSF Biosimilars Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global G-CSF Biosimilars Market Analysis by Regions
4.1 Global G-CSF Biosimilars Sales, Revenue and Market Share by Regions
4.1.1 Global G-CSF Biosimilars Sales and Market Share by Regions (2013-2018)
4.1.2 Global G-CSF Biosimilars Revenue and Market Share by Regions (2013-2018)
4.2 North America G-CSF Biosimilars Sales and Growth Rate (2013-2018)
4.3 Europe G-CSF Biosimilars Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific G-CSF Biosimilars Sales and Growth Rate (2013-2018)
4.5 South America G-CSF Biosimilars Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa G-CSF Biosimilars Sales and Growth Rate (2013-2018)
5 North America G-CSF Biosimilars by Countries
5.1 North America G-CSF Biosimilars Sales, Revenue and Market Share by Countries
5.1.1 North America G-CSF Biosimilars Sales and Market Share by Countries (2013-2018)
5.1.2 North America G-CSF Biosimilars Revenue and Market Share by Countries (2013-2018)
5.2 United States G-CSF Biosimilars Sales and Growth Rate (2013-2018)
5.3 Canada G-CSF Biosimilars Sales and Growth Rate (2013-2018)
5.4 Mexico G-CSF Biosimilars Sales and Growth Rate (2013-2018)
6 Europe G-CSF Biosimilars by Countries
6.1 Europe G-CSF Biosimilars Sales, Revenue and Market Share by Countries
6.1.1 Europe G-CSF Biosimilars Sales and Market Share by Countries (2013-2018)
6.1.2 Europe G-CSF Biosimilars Revenue and Market Share by Countries (2013-2018)
6.2 Germany G-CSF Biosimilars Sales and Growth Rate (2013-2018)
6.3 UK G-CSF Biosimilars Sales and Growth Rate (2013-2018)
6.4 France G-CSF Biosimilars Sales and Growth Rate (2013-2018)
6.5 Russia G-CSF Biosimilars Sales and Growth Rate (2013-2018)
6.6 Italy G-CSF Biosimilars Sales and Growth Rate (2013-2018)
7 Asia-Pacific G-CSF Biosimilars by Countries
7.1 Asia-Pacific G-CSF Biosimilars Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific G-CSF Biosimilars Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific G-CSF Biosimilars Revenue and Market Share by Countries (2013-2018)
7.2 China G-CSF Biosimilars Sales and Growth Rate (2013-2018)
7.3 Japan G-CSF Biosimilars Sales and Growth Rate (2013-2018)
7.4 Korea G-CSF Biosimilars Sales and Growth Rate (2013-2018)
7.5 India G-CSF Biosimilars Sales and Growth Rate (2013-2018)
7.6 Southeast Asia G-CSF Biosimilars Sales and Growth Rate (2013-2018)
8 South America G-CSF Biosimilars by Countries
8.1 South America G-CSF Biosimilars Sales, Revenue and Market Share by Countries
8.1.1 South America G-CSF Biosimilars Sales and Market Share by Countries (2013-2018)
8.1.2 South America G-CSF Biosimilars Revenue and Market Share by Countries (2013-2018)
8.2 Brazil G-CSF Biosimilars Sales and Growth Rate (2013-2018)
8.3 Argentina G-CSF Biosimilars Sales and Growth Rate (2013-2018)
8.4 Colombia G-CSF Biosimilars Sales and Growth Rate (2013-2018)
9 Middle East and Africa G-CSF Biosimilars by Countries
9.1 Middle East and Africa G-CSF Biosimilars Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa G-CSF Biosimilars Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa G-CSF Biosimilars Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia G-CSF Biosimilars Sales and Growth Rate (2013-2018)
9.3 UAE G-CSF Biosimilars Sales and Growth Rate (2013-2018)
9.4 Egypt G-CSF Biosimilars Sales and Growth Rate (2013-2018)
9.5 Nigeria G-CSF Biosimilars Sales and Growth Rate (2013-2018)
9.6 South Africa G-CSF Biosimilars Sales and Growth Rate (2013-2018)
10 Global G-CSF Biosimilars Market Segment by Type
10.1 Global G-CSF Biosimilars Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global G-CSF Biosimilars Sales and Market Share by Type (2013-2018)
10.1.2 Global G-CSF Biosimilars Revenue and Market Share by Type (2013-2018)
10.2 Human Growth Hormone Sales Growth and Price
10.2.1 Global Human Growth Hormone Sales Growth (2013-2018)
10.2.2 Global Human Growth Hormone Price (2013-2018)
10.3 Erythropoietin Sales Growth and Price
10.3.1 Global Erythropoietin Sales Growth (2013-2018)
10.3.2 Global Erythropoietin Price (2013-2018)
10.4 Monoclonal Antibodies Sales Growth and Price
10.4.1 Global Monoclonal Antibodies Sales Growth (2013-2018)
10.4.2 Global Monoclonal Antibodies Price (2013-2018)
10.5 Insulin Sales Growth and Price
10.5.1 Global Insulin Sales Growth (2013-2018)
10.5.2 Global Insulin Price (2013-2018)
10.6 Interferon Sales Growth and Price
10.6.1 Global Interferon Sales Growth (2013-2018)
10.6.2 Global Interferon Price (2013-2018)
10.7 Granulocyte-Colony Stimulating Factor Sales Growth and Price
10.7.1 Global Granulocyte-Colony Stimulating Factor Sales Growth (2013-2018)
10.7.2 Global Granulocyte-Colony Stimulating Factor Price (2013-2018)
11 Global G-CSF Biosimilars Market Segment by Application
11.1 Global G-CSF Biosimilars Sales Market Share by Application (2013-2018)
11.2 Blood Disorders Sales Growth (2013-2018)
11.3 Oncology Diseases Sales Growth (2013-2018)
11.4 Chronic And Autoimmune Diseases Sales Growth (2013-2018)
11.5 Growth Hormone Deficiencies Sales Growth (2013-2018)
12 G-CSF Biosimilars Market Forecast (2018-2023)
12.1 Global G-CSF Biosimilars Sales, Revenue and Growth Rate (2018-2023)
12.2 G-CSF Biosimilars Market Forecast by Regions (2018-2023)
12.2.1 North America G-CSF Biosimilars Market Forecast (2018-2023)
12.2.2 Europe G-CSF Biosimilars Market Forecast (2018-2023)
12.2.3 Asia-Pacific G-CSF Biosimilars Market Forecast (2018-2023)
12.2.4 South America G-CSF Biosimilars Market Forecast (2018-2023)
12.2.5 Middle East and Africa G-CSF Biosimilars Market Forecast (2018-2023)
12.3 G-CSF Biosimilars Market Forecast by Type (2018-2023)
12.3.1 Global G-CSF Biosimilars Sales Forecast by Type (2018-2023)
12.3.2 Global G-CSF Biosimilars Market Share Forecast by Type (2018-2023)
12.4 G-CSF Biosimilars Market Forecast by Application (2018-2023)
12.4.1 Global G-CSF Biosimilars Sales Forecast by Application (2018-2023)
12.4.2 Global G-CSF Biosimilars Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure G-CSF Biosimilars Picture
Table Product Specifications of G-CSF Biosimilars
Figure Global Sales Market Share of G-CSF Biosimilars by Types in 2017
Table
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
